What is BioConsortia?
BioConsortia operates at the intersection of microbiology and industrial agriculture, utilizing a proprietary platform to identify and deploy microbial consortia that enhance plant performance. The company's research pipeline is strategically focused on critical areas such as nitrogen, phosphorus, potassium, and sulfur fertilizer substitution, alongside traits for abiotic stress tolerance and biotic resistance. By partnering with established seed and crop protection entities, BioConsortia effectively bridges the gap between laboratory-scale microbial science and large-scale, sustainable field production. Its market position is defined by its ability to deliver measurable improvements in harvestable yield and root mass, addressing the urgent global demand for more efficient and environmentally resilient farming practices.
How much funding has BioConsortia raised?
BioConsortia has raised a total of $63.3M across 6 funding rounds:
Series B
$15M
Series C
$8M
Series D
$10M
Debt
$350K
Other Financing Round
$15M
Other Financing Round
$15M
Series B (2014): $15M with participation from Khosla Ventures and Otter Capital LLC
Series C (2016): $8M led by Otter Capital LLC and Khosla Ventures
Series D (2018): $10M supported by Otter Capital and Khosla Ventures
Debt (2020): $350K featuring PPP
Other Financing Round (2024): $15M backed by Otter Capital
Other Financing Round (2025): $15M with participation from Otter Capital
Key Investors in BioConsortia
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, specializing in breakthrough technologies across sectors including agriculture, sustainable energy, and robotics.
Otter Capital
A private equity firm led by John Pasquesi with a specialized focus on developing leading-edge agriculture and food production companies.
PPP
Public-Private Partnership
What's next for BioConsortia?
With the infusion of this latest capital, BioConsortia is well-positioned to accelerate its commercialization efforts and expand its research footprint. The company's strategic roadmap likely involves scaling its pipeline products to meet the requirements of global agricultural partners, further validating its microbial technology in diverse climatic conditions. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward deepening its intellectual property portfolio and optimizing its go-to-market strategy for fertilizer-alternative products. Continued support from its core investor base suggests a high degree of confidence in the company's ability to disrupt traditional chemical-dependent agricultural models with biological alternatives.
See full BioConsortia company page
